Bazedoxifene (Wyeth).
Article Details
- CitationCopy to clipboard
Gruber C, Gruber D
Bazedoxifene (Wyeth).
Curr Opin Investig Drugs. 2004 Oct;5(10):1086-93.
- PubMed ID
- 15535430 [ View in PubMed]
- Abstract
Bazedoxifene is a tissue-specific selective estrogen receptor modulator being developed by Wyeth Pharmaceuticals (formerly Wyeth-Ayerst Laboratories) to be used alone for the prevention and treatment of osteoporosis in postmenopausal women and in combination with Premarin for menopausal symptoms. As of March and June 2004, worldwide phase III trials for bazedoxifene, and bazedoxifene in combination with Premarin, were ongoing.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Bazedoxifene Estrogen receptor alpha Protein Humans YesAntagonistAgonistDetails